查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771707

灰指甲市場規模、佔有率、趨勢分析報告：按類型、治療方法、地區、細分市場預測，2025-2033

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

灰指甲市場的成長與趨勢：

根據Grand View Research的最新報告，全球甲癬市場規模預計到2033年將達到57.4億美元。預計2025年至2033年期間，該市場的複合年成長率將達到4.7%。甲癬市場的成長歸因於甲癬和慢性疾病發病率的上升，以及人們對治療的認知的提高。由於感染疾病會導致心理和社會影響，限制個人的工作和社交生活，因此為感染疾病患者提供有效且高效的治療至關重要，這進一步推動了市場的成長。

甲癬發生率的上升是推動整體市場成長的主要因素。這種感染疾病通常被稱為甲癬或真菌性指甲感染疾病，影響美國超過14%的總人口。然而，儘管甲癬具有高度傳染性，且患病風險會隨著老齡化成長而增加，但大多數人並未意識到甲癬的危害。

全球灰指甲組織等國際組織正與世界各地的公共衛生部門和醫療保健專業人士合作，提高大眾對灰指甲的認知，並改善全球的預防和治療。這有望推動治療藥物的需求。美國疾病管制與預防中心 (CDC) 發起的「思考灰指甲」等政府舉措強調了在患者早期發現灰指甲等真菌疾病並確保適當治療的重要性。這導致灰指甲治療藥物的需求激增，預計將推動該國市場的成長。

此外，主要參與者正致力於合作與夥伴關係關係，以開發新型甲癬治療方法，並保持市場競爭力。例如，2022年8月，Moberg Pharma AB與Padagis Israel Agencies Ltd.簽署了分銷協議，授予Padagis在以色列甲癬治療藥物MOB-015的獨家分銷權。此外，旨在解決諸如提高患者依從性和減少劑量等問題的技術創新預計將推動市場成長。例如，Intas Pharmaceuticals於2021年10月以Itaspor-SB Forte/Subawin為品牌推出了全球首款高生物利用度ItraconazoleSB 100mg。預計此舉將顯著提高患者依從性並降低治療成本。

灰指甲市場報告重點

  • 預計遠端甲下甲癬領域將在 2024 年佔據市場主導地位，這得益於 FDA 批准的非專利核准數量的增加和普及度的提高，以滿足日益成長的需求。
  • 由於使用和管理方便，外用藥物部分預計將在預測期內以最快的速度成長，從而提高患者的治療依從性。
  • 競爭對手正專注於獲取資本密集的專業能力，以加強和維持其競爭地位。
  • 2024 年，北美佔據了最大的市場佔有率，這得益於其良好的醫療保健條件、廣泛的目標人口以及高滲透率的治療。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章 灰指甲市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 灰指甲市場：按類型分類的業務分析

  • 2025 年及 2033 年各類型市場佔有率
  • 類型細分儀表板
  • 按類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 遠端甲下甲癬
  • 白色淺層甲癬
  • 近端甲下甲癬
  • 其他類型

第5章 灰指甲市場：依治療的業務分析

  • 2025年和2033年的治療市場佔有率
  • 治療細分儀表板
  • 市場規模、預測與趨勢分析（治療，2021-2033 年）
  • 口服
  • 局部的
  • 其他

第6章 灰指甲市場：區域評估與趨勢分析

  • 2025年及2033年區域市場佔有率分析
  • 區域市場儀表板
  • 2021-2033年市場規模與預測趨勢分析：
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Bausch Health Companies Inc.
    • GSK plc
    • Abbott
    • Pfizer Inc
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Cipla
    • Merck &Co., Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-031-4

Onychomycosis Market Growth & Trends:

The global onychomycosis market size is anticipated to reach USD 5.74 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.7% from 2025 to 2033. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights:

  • Distal subungual onychomycosis segment dominated the market in 2024 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2024 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Onychomycosis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Onychomycosis Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Distal Subungual Onychomycosis
    • 4.4.1. Distal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.5. White Superficial Onychomycosis
    • 4.5.1. White Superficial Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.6. Proximal Subungual Onychomycosis
    • 4.6.1. Proximal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.7. Other Types
    • 4.7.1. Other Types Market, 2021 - 2033 (USD Million)

Chapter 5. Onychomycosis Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2021 - 2033 (USD Million)
  • 5.5. Topical
    • 5.5.1. Topical Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Onychomycosis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Onychomycosis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Onychomycosis Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Bausch Health Companies Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. GSK plc
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Abbott
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Bayer AG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Teva Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Cipla
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Novartis AG
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sun Pharmaceutical Industries Ltd.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global onychomycosis market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 6 North America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 8 North America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 9 U.S. onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 10 U.S. onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 11 Canada onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 12 Canada onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 13 Mexico onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 15 Europe onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 17 Europe onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 18 UK onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 19 UK onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 20 Germany onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 22 France onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 23 France onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 24 Italy onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 25 Italy onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 26 Spain onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 27 Spain onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 28 Norway onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 30 Denmark onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 31 Denmark onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 32 Sweden onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 33 Sweden onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 37 Japan onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 38 Japan onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 39 China onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 40 China onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 41 India onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 42 India onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 43 Australia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 44 Australia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 45 South Korea onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 46 South Korea onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 47 Thailand onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 48 Thailand onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 49 Latin America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 51 Latin America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 52 Brazil onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 53 Brazil onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 54 Argentina onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 55 Argentina onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 59 South Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 60 South Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 63 UAE onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 64 UAE onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 65 Kuwait onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait onychomycosis market, by treatment, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Onychomycosis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Onychomycosis market dynamics
  • Fig. 12 Onychomycosis market: Porter's five forces analysis
  • Fig. 13 Onychomycosis market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Distal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 16 White Superficial Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 17 Proximal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 18 Other Types market, 2021 - 2033 (USD Million)
  • Fig. 19 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Topical market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Onychomycosis market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework